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Abstract
Background: Roflumilast is an oral, selective phosphodiesterase 4 inhibitor with anti-inflammatory effects in
chronic obstructive pulmonary disease (COPD). The addition of roflumilast to long-acting bronchodilators improves
lung function in patients with moderate-to-severe COPD. The present study investigated drug-drug interaction
effects between inhaled formoterol and oral roflumilast.
Methods: This was a single-centre (investigational clinic), open, randomised, multiple-dose, parallel-group study. In
Regimen A, healthy men were treated with roflumilast (500 μg tablet once daily; Day 2-18) and concomitant
formoterol (24 μg twice daily; Day 12-18). In Regimen B, healthy men were treated with formoterol (24 μg twice
daily; Day 2-18) and concomitant roflumilast (500 μg once daily; Day 9-18). Steady-state plasma pharmacokinetics
of roflumilast, roflumilast N-oxide and/or formoterol (Cmax and AUC0-τ) as well as pharmacodynamics - blood
pressure, transthoracic impedance cardiography (ZCG), 12-lead digital electrocardiography, peripheral blood
eosinophils, and serum glucose and potassium concentrations - were evaluated through Day 1 (baseline), Day 8
(Regimen B: formoterol alone) or Day 11 (Regimen A: roflumilast alone), and Day 18 (Regimen A and B: roflumilast
plus formoterol). Blood and urine samples were taken for safety assessment at screening, pharmacokinetic profiling
days and Day 19. Adverse events were monitored throughout the study.
Results: Of the 27 subjects enrolled, 24 were evaluable (12 in each regimen). No relevant pharmacokinetic
interactions occurred. Neither roflumilast nor formoterol were associated with significant changes in cardiovascular
parameters as measured by ZCG, and these parameters were not affected during concomitant administration.
Formoterol was associated with a slight increase in heart rate and a corresponding shortening of the QT interval,
without changes in the heart rate-corrected QTc interval. There were small effects on the other pharmacodynamic
assessments when roflumilast and formoterol were administered individually, but no interactions or safety concerns
were seen after concomitant administration. No severe or serious adverse events were reported, and no adverse
events led to premature study discontinuation.
Conclusions: No clinically relevant pharmacokinetic or pharmacodynamic interactions were found when oral
roflumilast was administered concomitantly with inhaled formoterol, including no effect on cardiac repolarisation.
Roflumilast was well tolerated.
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* Correspondence: gezim.lahu@nycomed.com
2Nycomed GmbH, Konstanz, Germany
Full list of author information is available at the end of the article
de Mey et al. BMC Clinical Pharmacology 2011, 11:7
http://www.biomedcentral.com/1472-6904/11/7
© 2011 de Mey et al; licensee BioMed Central Ltd. This is an Open Access article distributed under the terms of the Creative Commons
Attribution License (http://creativecommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and reproduction in
any medium, provided the original work is properly cited.Background
Roflumilast (3-cyclopropylmethoxy-N-(3,5-dichloropyri-
din-4-yl)-4-(difluoromethoxy)benzamide; CAS Registry
number: 162401-32-3; molecular formula: C17H14Cl2
F2N2O3) is a selective, oral, once-daily phosphodiesterase
4 (PDE4) inhibitor that has shown anti-inflammatory
activity in pre-clinical studies [1-4], and in patients with
chronic obstructive pulmonary disease (COPD) [5]. In
large randomised clinical studies, roflumilast consistently
improved lung function in patients with moderate-to-
severe COPD [6], severe COPD [7], or severe airflow
obstruction plus chronic bronchitis [8] compared with
placebo.
Long-acting bronchodilators such as the b2-adrenocep-
tor agonists formoterol and salmeterol and the anticholi-
nergic tiotropium [9-11] are central to the treatment of
COPD; however, some patients have poor symptom con-
trol with these agents, particularly patients with more
severe disease [12]. Two large clinical trials have investi-
gated whether the addition of roflumilast improves lung
function in patients with moderate-to-severe COPD who
are already receiving long-acting bronchodilators [13]. In
these trials, patients already receiving salmeterol or tio-
tropium were randomised to receive either oral roflumi-
last 500 μg or placebo once daily for 24 weeks, in
addition to continued salmeterol or tiotropium treatment
[13]. Compared with placebo, the addition of roflumilast
improved mean pre-bronchodilator forced expiratory
volume in both trials (p < 0.0001). Further, in a separate
in vitro study, formoterol increased the inhibitory effect
of roflumilast on cytokine and tumour necrosis factor-a
production from human parenchymal and bronchial
explants [14].
Both PDE inhibitors and b2-adrenoceptor agonists
lead to an accumulation of intracellular cyclic adenosine
monophosphate [15-17], which plays a key role in the
regulation of cardiac function [18]. It is known that
b2-adrenoceptor agonists are associated with adverse
cardiac events [19]. In contrast, a previous study demon-
strated that roflumilast had no significant effect on car-
diac repolarisation (QT/QTc interval) in healthy
subjects [20].
When administered as a single, oral 500 μgd o s e ,
roflumilast is readily and almost totally absorbed in
healthy individuals, with a mean bioavailability of 79%
[21] and dose-proportional pharmacokinetics observed
within the 250-1000 μg dose range [22]. Repeated-dose
pharmacokinetic profiles of roflumilast and its active
metabolite roflumilast N-oxide have been well charac-
terised, with median time to maximum plasma concen-
tration (tmax) values of 1 hour and 8 hours, respectively,
and median effective plasma half-lives of 17 hours and
30 hours, respectively [22-24]. Roflumilast N-oxide has a
PDE selectivity profile and potency in vivo similar to
that of roflumilast, and a substantially (10-fold) greater
area under the plasma concentration-time curve (AUC)
[4,22]. It is therefore estimated to account for about
90% of the overall PDE4 inhibitory activity of roflumi-
last. To estimate the combined PDE4 inhibition of roflu-
milast and roflumilast N-oxide in humans following
administration of roflumilast, the parameter termed
‘total PDE4 inhibitory activity’ (tPDE4i) has been estab-
lished [23,25]. This parameter represents the sum of the
overall exposure to roflumilast and roflumilast N-oxide
by accounting for differences in intrinsic activity (IC50),
free fraction (protein binding) and in vivo exposure
(AUC values) of both compounds.
Roflumilast is metabolised to roflumilast N-oxide
mainly through biotransformation via the cytochrome
P450 (CYP) enzymes CYP3A4 and CYP1A2, and roflu-
milast N-oxide is cleared by CYP3A4. The CYP3A4
inhibitors erythromycin and ketoconazole have been
shown to increase tPDE4i by 8-9% [26,27]; the CYP1A2
inhibitor fluvoxamine and the dual CYP3A4/1A2 inhibi-
tors enoxacin and cimetidine increase tPDE4i by 59%,
25% and 47%, respectively [28-30]. Conversely, adminis-
tration of the cytochrome P450 enzyme inducer rifampi-
cin results in a reduction in tPDE4i by 58% [31].
Roflumilast and formoterol have a low potential for
pharmacokinetic interaction because formoterol is elimi-
nated mainly by direct glucuronidation and does not
inhibit CYP isoenzymes at therapeutically relevant con-
centrations [32]. Following inhalation, formoterol is
rapidly absorbed, with plasma concentrations increasing
linearly with dose [32]. The kinetics of formoterol are
similar after single and repeated administration, indicat-
ing no auto-induction or inhibition of metabolism [32];
however, there is a modest and self-limiting accumula-
tion in plasma after repeated dosing in patients with
COPD [32]. In a previous Phase I study, no apparent
drug-drug interaction was found between roflumilast
and orally co-administered formoterol (unpublished
data; Nycomed GmbH, 2002). The nature and extent of
a pharmacokinetic drug-drug interaction may, however,
differ when formoterol is inhaled [33].
Since roflumilast is likely to be used concomitantly
with a b2-adrenoceptor agonist in some patients, it is of
interest to investigate whether and to what extent con-
comitant administration results in relevant pharmacoki-
netic and pharmacodynamic drug-drug interactions with
a focus on cardiovascular effects.
Methods
The protocol (Clinicaltrials.gov registration NCT
00940329) was reviewed and approved by an independent
ethics committee (Ethik-Kommission Landesärztekammer
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Mainz, Germany) and competent health authorities
(Bundesinstitut für Arzneimittel und Medizinprodukte
[BfArM] Fachregistratur Klinische Prüfung, Bonn, Ger-
many). The study was planned, conducted, analysed and
reported in accordance with the principles of Good Clini-
cal Practice, the Declaration of Helsinki and the provisions
for the orderly conduct of clinical trials in the country of
conduct.
Subjects
Eligibility of subjects was evaluated on the basis of an
extensive screening investigation performed within 3
weeks before admission to the study clinic, which
included demography, medical history, review of co-
medications, physical examination, recumbent blood
pressure and pulse rate, electrocardiograms (ECGs), and
laboratory safety tests (haematology, clinical chemistry,
urinalysis, hepatitis and HIV serology).
Eligible subjects included Caucasian males aged 18 to
45 years with a body mass index between 18 and 30 kg/
m
2, and a body weight of > 50 kg. All subjects were will-
ing and able to provide informed consent.
Exclusion criteria were as follows: previous participa-
tion in the study or in any other study; donation of
blood or plasma within the last 30 days; presence of
acute or chronic disease; presence of clinically relevant
findings in the laboratory tests (including hepatitis and
HIV serology and tests for alcohol and social drugs);
signs or history of cardiac disease including QTc inter-
val (Bazett’s correction) ≥ 430 ms and PQ interval ≥ 220
ms; susceptibility to symptomatic orthostatic hypoten-
sion; previous gastrointestinal surgery other than appen-
dectomy and herniotomy; use of any medication within
the last 2 weeks or within less than 10 times the elimi-
nation half-life of the respective drug; history of any
clinically relevant hypersensitivity (in particular to for-
moterol or other b2-adrenoceptor agonists, to roflumi-
last or to any inactive ingredient in the trial
medication); smoking more than 10 cigarettes/day or
equivalent; evidence or suspicion of alcohol or social
drug abuse; excessive xanthine consumption; and any
concern of lack of compliance or willingness to adhere
to the study directives and restrictions.
Interventions
This was an open-label, randomised, actively controlled,
multiple-dose, parallel-group study with a fixed-adminis-
tration sequence. Screening took place between Day -21
and Day -1; the study period lasted from Day -1 to Day
19; and the post-study examination was conducted
within 1 week of the last intake of the study medication.
Subjects were admitted to the clinic from the evening of
Day -1 to the morning of Day 19. Subjects were
instructed to avoid strenuous physical exercise from Day
-3 until the post-study examination. Smokers were
required to keep their smoking habits stable, but were
not allowed to smoke during the main profiling days.
Alcohol- and caffeine-containing beverages, as well as
grapefruit juice, were not allowed from Day -2 to Day
19. In compliance with European guidelines, both drugs
were given at the maximum recommended therapeutic
dosage.
For Regimen A, subjects received 500 μg oral roflumi-
last once daily (daily dose: one tablet of roflumilast 500
μg) from the morning of Day 2 to the morning of Day
18. From the morning of Day 12 to the evening of Day
18 subjects also received 24 μg formoterol for oral inha-
lation delivered by a dry powder inhaler (DPI) device
(Foradil
® P, Novartis Pharma GmbH, Vienna, Austria)
twice daily, once in the morning and once in the eve-
ning (daily dose: 48 μg formoterol). For Regimen B, sub-
jects received 24 μg formoterol for oral inhalation
delivered by a DPI device (Foradil
® P) twice daily, once
in the morning and once in the evening from the morn-
ing of Day 2 to the evening of Day 18. From the morn-
ing of Day 9 to the morning of Day 18 subjects also
received 500 μg roflumilast once daily. The start of the
concomitant phases for each regimen was dependent on
the pharmacokinetic characteristics of roflumilast and
formoterol; as more time is needed to achieve steady
state for roflumilast than formoterol, the timings were
different between Regimen A and Regimen B.
Roflumilast was taken orally with 240 mL plain water
after an overnight fast and rest; after intake, a mouth
check was performed for compliance control. No fluids
were allowed within 2 hours after each dose on the
profile days. On days when the two medications were
co-administered, formoterol was administered within 1
minute of roflumilast being administered.
The main profiling days were scheduled on Days 1, 11
and 18 for Regimen A, and on Days 1, 8 and 18 for
Regimen B. On these days, subjects continued their fast
from the previous evening until 8 hours after morning
dosing, and standardised meals were served at 8 hours
(lunch) and 12.5 hours after morning dosing (dinner).
Pharmacokinetic methods
Blood samples for pharmacokinetic assessments were
t a k e no nD a y s1 1a n d1 8f o rR e g i m e nAa n dD a y s8
and 18 for Regimen B, 30 minutes before dosing and
0.25, 0.5, 1, 2, 4, 6, 8, 10 and 12 hours after dosing, with
additional samples taken at 14 and 24 hours for roflumi-
last (Days 11 and 18 for Regimen A, and Day 18 for
Regimen B). Pre-dose blood samples for determination
of trough levels were taken on Days 9 and 10 for Regi-
men A (morning only), and on Days 6 and 7 (morning
and evening) for Regimen B. Blood samples (4.5 mL)
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obtained by centrifugation at 1550 g for 15 minutes.
Plasma samples were stored at -20°C or below for roflu-
milast, and at -70°C for formoterol. Plasma concentra-
tions of roflumilast and roflumilast N-oxide were
determined using high-performance liquid chromatogra-
phy coupled with tandem mass spectrometry (HPLC-
MS/MS). Before the sample analysis we determined that
formoterol did not interfere with the quantification of
roflumilast or roflumilast N-oxide. The lower limit of
quantitation (LLOQ) was 0.1 ng/L using a sample
volume of 0.4 mL for both roflumilast and roflumilast
N-oxide. The inter-day precision of this assay, as deter-
mined by the analysis of quality control (QC) samples,
ranged from 5.3% to 10.0% for both analytes. The inter-
day accuracy of the assay, as determined by the analysis
of the QC samples, ranged from -6.8% to +2.5% for
both analytes. Roflumilast and roflumilast N-oxide stan-
dard curves were valid up to 20 ng/mL and 40 ng/mL,
respectively. Determination of roflumilast and
roflumilast N-oxide was performed at Altana Pharma
AG, Konstanz, Germany (Nycomed GmbH). Plasma
concentrations of formoterol were determined using
HPLC-MS/MS. The LLOQ in plasma was 0.4 pg/mL
using a sample volume of 1.0 mL. Formoterol standard
curves were valid up to 99.9 pg/mL. The intra-day preci-
sion for QC samples ranged from 0.5% to 13.1%. The
intra-day accuracy of the formoterol QC samples ranged
from -10.5% to +13.6%, the inter-day precision from
6.4% to 7.6%, and the inter-day accuracy from 0.7% to
7.1%. Determination of formoterol was performed at
pharm-analyt Labor GmbH, Baden, Austria, under the
supervision of Altana Pharma AG(Nycomed GmbH).
For roflumilast, roflumilast N-oxide and formoterol,
the maximum plasma concentration (Cmax)w a sd e r i v e d
directly from the plasma concentrations. The AUC from
time zero to the time of the last quantifiable concentra-
tion, which corresponded to the dosing interval of each
analyte (AUC0-τ), was estimated using the linear trape-
zoidal method. Apparent clearance at steady state (CL/F;
calculated by dose/AUCτ) was reported for roflumilast
only. Pharmacokinetic variables were calculated by non-
compartmental analysis using WinNonLin professional,
version 4.01 (PharSight, Mountain View, California,
USA). The calculation of tPDE4i was based on the equa-
tion described in Lahu et al. [27].
Cardiovascular methods: blood pressure and transthoracic
impedance cardiography
Cardiovascular effects were evaluated non-invasively by
means of ECGs (cardiac rhythm, intra-cardiac conduc-
tion and ventricular repolarisation), oscillometric blood
pressure and transthoracic impedance cardiography
(ZCG; systolic time intervals, contractility indices and
estimates of stroke volume and cardiac output). Cardio-
vascular assessments (oscillometric blood pressure, pulse
rate, 12-lead ECG, and three-lead ZCG) were recorded
b e f o r ed o s i n ga n da t1 0 ,2 0 ,4 0a n d6 0m i n u t e s ,a n da t
2, 3, 4, 5, 6, 7 and 8 hours after morning dosing. Blood
pressure, pulse rate and ECGs were also assessed at 12
hours after dosing, and on the morning of Day 19. All
cardiovascular measurements were carried out after the
subjects had been recumbent for at least 10 minutes;
they generally stayed in bed from 1 hour before until 8
hours after morning dosing.
Systolic time intervals (STIs) and ZCG estimates of
the systolic cardiac pump performance were derived
from the simultaneous registration of a one-lead ECG, a
phonocardiogram (PCG), and the rate of change of the
transthoracic impedance (dZ/dt) to an AC current
applied through the thoracic cage (CARDIODYNA-
GRAPH; Diefenbach GmbH, Wiesbaden, Germany).
Tracings were captured and stored digitally during the
study and subsequently analysed after the study by dis-
playing the analogue ECG, PCG and ZCG signals on a
computer screen. The relevant signal amplitudes and
time intervals were delineated manually by operator-
steered cursors; measurements were made for at least 10
artefact-free consecutive cardiac cycles [34,35]. From
these tracings, the following variables were derived by
direct measurement: RR interval (ms), total electrome-
chanic systole (QS2 [ms]), ventricular ejection time
(VET [ms]), baseline transthoracic impedance (Z0 [Ω]),
and maximum negative velocity of transthoracic impe-
dance changes during the cardiac cycle (dZ/dtmax [Ω/s]).
These variables were analysed for the 10 cycles and
their means were used in the calculations of the follow-
ing variables: heart rate (HR [bpm]), pre-ejection period
(PEP [ms] = QS2 - VET), HR-corrected STIs (STIc and
STIi according to Weissler et al. [36]), ZCG estimates of
stroke volume (SV [mL] according to Kubicek’s equation
[37] using the equation of Geddes and Sadler for the
specific resistance of blood [38]), cardiac output (CO
[mL/min]), and total peripheral resistance (TPR [dyn.s.
cm
-5]). For the latter variable, the mean blood pressure
(MBP [mmHg]) was used as calculated according to
Wezler and Böger [39] from the systolic blood pressure
(mmHg) and the diastolic blood pressure (mmHg).
ZCG analysis was carried out by a single analyst who
was blinded with regard to subject, study regimen, pro-
filing day within regimen, and time during the day. The
time courses of ZCG variables were evaluated in two
main data formats: untransformed (U, all profiling days)
and time-matched for control Day 1 (δ, profiling days
except control Day 1); the time courses of U- and δ-
data were characterised by their morning pre-dose base-
line values (BLU and BLδ) and the observed minimum
(dmin) and maximum (dmax) values over the post-dosing
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a n dT P R )w e r ec o m p a r e db yn on-parametric estimates
of the differences between the profiling days (point esti-
mate and 95% confidence interval [CI] according to
Hodges and Lehmann) [40].
Electrocardiography
Digital 12-lead ECGs were recorded immediately after
each ZCG recording. Tracings were analysed off-study
by regimen-blinded qualified analysts, using previously
reported methodology [20]. For each time point, three
cycles were measured with regard to the RR, PQ and
QT-intervals [ms]. The means of the three measure-
ments were used for the calculation of HR and HR-cor-
rected QTc intervals, according to Bazett’se q u a t i o n
(QTcB = QT/RR
1/2)[ 4 1 ]a n dF r i d e r i c i a ’se q u a t i o n
(QTcF = QT/RR
1/3) [41,42].
Biological markers
During the main profiling days, blood was sampled at
each ZCG time point for the determination of serum
glucose and potassium concentrations. Samples were
also collected 12 and 24 hours after morning dosing.
Safety and tolerability
Blood and urine samples for conventional clinical
laboratory safety tests were obtained at the screening
visit, in the morning of each main profiling day, and on
D a y1 9 .A d v e r s ee v e n t s( A E s )w e r em o n i t o r e dt h r o u g h -
out the study.
Results
Subjects
Twenty-seven healthy male subjects were enrolled and
received the assigned investigational medication at least
once (see Table 1 for demographic data). For Regimen
A, 12 subjects were enrolled and all completed the
study in accordance with the protocol specifications. For
Regimen B, 15 subjects were enrolled: one withdrew
consent on Day 11 and two were discontinued prema-
turely after erroneous dosing on Day 2, leaving 12 sub-
jects who completed the study in accordance with the
protocol.
Pharmacokinetics
T h et i m ec o u r s e so fg e o m e t r i cm e a np l a s m ac o n c e n t r a -
tions of roflumilast, roflumilast N-oxide and formoterol
a r es h o w ni nF i g u r e s1 ,2a n d3 .G e o m e t r i cm e a n sa n d
their 68% ranges of steady-state pharmacokinetics of
roflumilast, roflumilast N-oxide and formoterol are
shown in Tables 2 and 3. There were no relevant changes
in steady-state pharmacokinetics of roflumilast and roflu-
milast N-oxide when formoterol was added; similarly,
there were no changes in steady-state pharmacokinetics
of formoterol when roflumilast was added. There were
some between-group effects, since steady-state AUC and
Cmax values for roflumilast and roflumilast N-oxide were
about 10-15% lower when roflumilast was co-adminis-
tered with formoterol (Regimen B, Day 18), compared
with roflumilast alone (Regimen A, Day 11) or roflumilast
after addition of formoterol (Regimen A, Day 18).
Impedance cardiography
Regimen A
The treatment medians for baseline Day 1, roflumilast
monotherapy alone (R; Day 11), and concomitant roflu-
milast plus formoterol treatment (R+F; Day 18) are
shown in Table 4 for untransformed morning pre-dos-
ing values, untransformed dmax and dmin post-dosing
values (including contrast of R vs D1), and time-
matched dmax and dmin post-dosing values (including
contrast of R+F vs R).
Roflumilast alone had little effect on cardiovascular
function and there were only small changes in the ZCG/
STI variables. Concomitant administration of formoterol
resulted in a protracted rise in HR compared with roflu-
milast alone (Figure 4), which was associated with a rise
in CO (Figure 5) and a drop in TPR within 10 minutes
(Figure 6). Formoterol co-administration was also asso-
ciated with an increase in dZ/dtmax, particularly in the
first hour after dosing, and an overall shortening of QS2
and PEP, which were mostly related to the rise in HR
since they were less evident for the HR-corrected STIs
(Table 4). These changes were small and within the nor-
mal physiological range.
Regimen B
The treatment medians for baseline Day 1, formoterol
monotherapy alone (F; Day 8) and concomitant formo-
terol plus roflumilast (F+R; Day 18) and their contrasts
are shown in Table 5. Compared with baseline, formo-
terol administration was associated with an increase in
HR (Figure 4), a rise in CO (Figure 5) and a decrease in
Table 1 Subject demographics for the study population
(all enrolled subjects)
Characteristic Regimen A (n =
12)
Regimen B (n =
15)
Male, n (%) 12 (100) 15 (100)
Caucasian, n (%) 12 (100) 15 (100)
Age, years (median [range]) 33 (25-44) 33 (21-44)
Body height, cm (median [range]) 184 (169-192) 180 (168-185)
Body weight, kg (median [range]) 83 (66-95) 75 (61-97)
Body mass index, kg/m
2 (median
[range])
25 (23-28) 24 (21-30)
Smoking status, n
Ex-smoker 2 4
Current 3 6
Never 7 5
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dZ/dtmax, and an overall shortening in QS2 and PEP.
These effects were clearly apparent on Day 8 and were
not amplified by the concomitant administration of
roflumilast.
Electrocardiograms
Both roflumilast and formoterol were associated with a
slight increase in HR and, correspondingly, a decrease in
the duration of the QT interval. QTc values, either
uncorrected or corrected using Bazett’sf o r m u l ao r
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Figure 1 Time course of the geometric mean (68% range) plasma concentrations of roflumilast (linear scale). R alone: roflumilast 500 μg
once daily at steady state (Regimen A: Day 11; n = 12); RF: roflumilast 500 μg once daily and formoterol 24 μg twice daily at steady state
(Regimen A: Day 18; n = 12); FR: formoterol 24 μg twice daily and roflumilast 500 μg once daily at steady state (Regimen B: Day 18; n = 12).
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Figure 2 Time course of the geometric mean (68% range) plasma concentrations of roflumilast N-oxide (linear scale). R alone:
roflumilast 500 μg once daily at steady state (Regimen A: Day 11; n = 12); RF: roflumilast 500 μg once daily and formoterol 24 μg twice daily at steady
state (Regimen A: Day 18; n = 12); FR: formoterol 24 μg twice daily and roflumilast 500 μg once daily at steady state (Regimen B: Day 18; n = 12).
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changes. Categorical analyses of QT/QTc interval data
did not reveal differences in the incidence of outliers
between regimens, and the incidence of outliers was
small. None of the subjects developed abnormal QT/
QTc prolongation, and all QT/QTc intervals remained
below 450 ms. No clinically relevant drug-related
changes in PR or QRS intervals were observed. No clini-
cally relevant regimen-related changes in ECG waveform
morphology were detected.
Serum glucose
With Regimen A, the median pre-dose serum glucose
decreased from Day 1 (4.97 mmol/L) to Day 11 (4.75
mmol/L) and Day 18 (4.52 mmol/L). During Day 11
(roflumilast alone), glucose levels tended to remain
slightly lower than pre-dose levels; in contrast, on Day
18, with concomitant formoterol plus roflumilast, there
was a post-dose increase in serum glucose level that was
close to the values throughout Day 1 (although the pre-
dose levels had been lower).
30
25
20
15
10
G
e
o
m
e
t
r
i
c
 
m
e
a
n
 
(
μ
g
/
L
)
5
0
04 26
Time (hours)
81 0 1 2
Regimen A (Day 18)
Regimen B (Day 8)
Regimen B (Day 18)
Figure 3 Time course of the geometric mean (68% range) plasma concentrations of formoterol (linear scale). Regimen A: Day 18
(roflumilast 500 μg once daily and formoterol 24 μg twice daily at steady state; n = 12); Regimen B: Day 8 (formoterol 24 μg twice daily at
steady state; n = 13) and Day 18 (formoterol 24 μg twice daily and roflumilast 500 μg once daily at steady state; n = 12).
Table 2 Geometric means (68% inter-percentile range) of the main pharmacokinetic variables for roflumilast and
roflumilast N-oxide at steady state
Regimen A Regimen B
Day 11 (roflumilast alone)
(n = 12)
Day 18 (roflumilast plus formoterol)
(n = 12)
Day 18 (formoterol plus roflumilast)
(n = 12)
Roflumilast
C trough (μg/L) 0.53 (0.33-0.85) 0.50 (0.29-0.86) 0.37 (0.18-0.77)
Cmax (μg/L) 6.89 (4.94-9.62) 6.43 (4.79-8.63) 5.92 (4.27-8.22)
AUCτ (μg.h/L) 35.8 (27.8-46.1) 36.9 (28.1-48.4) 31.8 (21.2-47.7)
CL/F (L/h) 13.9 (10.8-17.9) 13.5 (10.3-17.7) 15.7 (10.4-23.5)
Roflumilast N-oxide
C trough (μg/L) 12.43 (8.24-18.76) 12.72 (8.18-19.79) 10.66 (6.29-18.06)
AUCτ (μg.h/L) 417 (299-582) 414 (293-584) 369 (254-537)
Cmax (μg/L) 23.3 (17.3-31.3) 23.7 (17.2-32.6) 22.04 (15.9-30.5)
AUCτ, area under the plasma concentration versus time curve; Cmax, maximum plasma concentration; Ctrough, trough plasma concentration; CL/F, apparent
clearance at steady state.
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Page 7 of 14Table 3 Geometric means (68% inter-percentile range) of the main pharmacokinetic variables for formoterol at steady
state
Regimen B Regimen A
Day 8 (formoterol alone)
(n = 13)
Day 18 (formoterol plus roflumilast)
(n = 12)
Day 18 (roflumilast plus formoterol)
(n = 12)
Formoterol
Ctrough (μg/L) 4.12 (3.05-5.57) 3.94 (3.13-4.96) 4.23 (2.43-7.38)
Cmax (μg/L) 16.7 (11.5-24.3) 17.2 (12.3-24.1) 18.7 (14.3-24.6)
AUCτ (μg.h/L) 96.7 (72.8-128) 93.1 (72.7-119) 93.2 (72.9-119)
AUCτ, area under the plasma concentration versus time curve; Cmax, maximum plasma concentration; Ctrough, trough plasma concentration.
Table 4 Pharmacodynamic measures - Regimen A: treatment medians and treatment contrasts
Untransformed pre-dose morning values
Median Point estimate (95% CI)
Variable Day 1 Day 11 (R) Day 18 (R+F) Day 11-Day 1 Day 18-Day 11 Day 18-Day 1
HR (bpm) 59 63 61 3 (-5 to 8) 1 (-1 to 6) 5 (-2 to 10)
PEP (ms) 106 94 95 -3 (-17 to 10) -4 (-13 to 6) -8 (-19 to 6)
QS2 (ms) 435 423 430 -10 (-21 to 2) -1 (-14 to 12) -12 (-23 to 4)
dZ/dt (Ω/s) 1.82 1.67 1.77 -0.06 (-0.29 to 0.16) 0.03 (-0.08 to 0.12) -0.05 (-0.26 to 0.15)
CO (L/min) 10.4 9.1 10.4 -0.6 (-1.7 to 0.5) 0.1 (-1.0 to 1.7) -0.3 (-1.0 to 0.6)
TPR (dyn.s.cm
-5) 755 838 706 14 (-98 to 121) -12 (-121 to 85) -4 (-93 to 84)
Untransformed post-dose maximum and minimum values
dmax (U) dmin (U)
Median Point estimate (95% CI) Median Point estimate (95% CI)
Variable Day 1 Day 11 (R) Day 18 (R+F) Day 11-Day 1 Day 1 Day 11 (R) Day 18 (R+F) Day 11-Day 1
HR (bpm) 62 64 70 3 (-4 to 6) 52 54 61 4 (1 to 7)
PEP (ms) 119 121 114 3 (-7 to 11) 86 86 81 0 (-9 to 13)
QS2 (ms) 457 454 432 -1 (-11 to 11) 416 410 399 -9 (-21 to 8)
dZ/dt (Ω/s) 2.09 1.93 2.06 -0.05 (-0.25 to 0.15) 1.59 1.56 1.62 0.03 (-0.18 to 0.20)
CO (L/min) 10.3 10.6 11.7 0.2 (-1.1 to 1.4) 7.6 8.3 8.8 -0.4 (-1.2 to 0.4)
TPR (dyn.s.cm
-5) 1013 934 877 47 (-124 to 178) 762 733 603 -18 (-96 to 43)
Day 1-matched post-dose maximum and minimum values
dmax (δ)d min (δ)
Median Point estimate (95% CI) Median Point estimate (95% CI)
Variable Day 11 (R) Day 18 (R+F) Day 18-Day 11 Day 11 (R) Day 18 (R+F) Day 18-Day 11
HR (bpm) 9 14 5 (-1 to 11) -4 0 5 (1 to 9)
PEP (ms) 25 19 -8 (-19 to 4) -27 -30 -2 (-11 to 10)
QS2 (ms) 19 4 -15 (-31 to -8) -34 -47 -14 (-29 to 1)
dZ/dt (Ω/s) 0.28 0.32 0.08 (-0.07 to 0.22) -0.10 -0.26 0.05 (-0.12 to 0.21)
CO (L/min) 1.6 2.6 0.8 (-0.7 to 2.3) -1.7 -1.2 0.3 (-0.6 to 1.8)
TPR (dyn.s.cm
-5) 126 108 -42 (-179 to 77) -128 -168 -42 (-131 to 43)
CO, cardiac output; dmax, post-dose maximum values; dmin, post-dose minimum values; dZ/dt, rate of change of the transthoracic impedance; HR, heart rate; PEP,
pre-ejection period; QS2, total electromechanic systole; TPR, total peripheral resistance.
Medians for baseline (Day 1), roflumilast alone (R; Day 11) and roflumilast plus formoterol (R+F; Day 18) with the corresponding point and 95% confidence
interval (CI) estimates for untransformed (U) morning pre-dose values, untransformed post-dose maximum and minimum values (dmax and dmin), and Day 1-
matched (δ) post-dose maximum and minimum values.
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Figure 4 Time course of the median heart rate throughout the main profiling days. Regimen A: baseline Day 1 (NO treatment), Day 11 (R
alone: roflumilast 500 μg once daily) and Day 18 (RF: roflumilast 500 μg once daily and formoterol 24 μg twice daily). Regimen B: baseline Day 1
(NO treatment), Day 8 (F alone: formoterol 24 μg twice daily) and Day 18 (FR: formoterol 24 μg twice daily and roflumilast 500 μg once daily).
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Figure 5 Time course of the median cardiac output (CO) estimated by transthoracic impedance cardiography throughout the main
profiling days. Regimen A: baseline Day 1 (NO treatment), Day 11 (R alone: roflumilast 500 μg once daily) and Day 18 (RF: roflumilast 500 μg
once daily and formoterol 24 μg twice daily). Regimen B: baseline Day 1 (NO treatment), Day 8 (F alone: formoterol 24 μg twice daily) and Day
18 (FR: formoterol 24 μg twice daily and roflumilast 500 μg once daily).
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Page 9 of 14With Regimen B, there was a slight post-dose increase
in serum glucose throughout Day 8 compared with Day
1; addition of roflumilast did not appear to change this
formoterol effect.
Serum potassium
With Regimen A, the median pre-dose serum potassium
level was lower during roflumilast administration (4.16
mmol/L) than at Day 1 (4.34 mmol/L) or during conco-
mitant administration of the two agents (4.35 mmol/L)
on Day 18. During Day 11, when roflumilast was admi-
nistered alone, serum potassium levels remained slightly
lower than levels throughout Day 1. On Day 18, with
concomitant formoterol plus roflumilast, serum potas-
sium levels tended to decrease from baseline, particu-
larly between 1 and 6 hours after morning dosing.
With Regimen B, pre-dose concentrations were similar
during formoterol administration (4.38 mmol/L) on Day
8 and during concomitant administration of formoterol
and roflumilast (4.32 mmol/L) on Day 18 compared
with Day 1 (4.48 mmol/L). On both Day 8 (formoterol)
and Day 18 (concomitant administration), serum potas-
sium levels tended to decrease from baseline throughout
the course of the day.
Safety
For Regimen A, during administration of roflumilast
alone (Day 2 to Day 11), 7 subjects experienced 17 AEs;
during subsequent concomitant administration of roflu-
milast and formoterol (Day 12 to Day 18), 8 subjects
experienced 22 AEs. The most common AE was tremor,
which was seen exclusively after addition of formoterol
to roflumilast (11 of 22 AEs). Dizziness and myalgia
were each reported on four occasions when roflumilast
was administered alone; myalgia was also reported on
four occasions when formoterol was added.
For Regimen B, during administration of formoterol
a l o n e( D a y2t oD a y8 ) ,n oA E sw e r er e p o r t e d .S u b s e -
quently, during concomitant administration of formo-
terol and roflumilast (Day 9 to Day 18), 17 AEs were
reported for 6 subjects; dizziness and headache were
each reported on five occasions and tremor on two
occasions.
All AEs were considered to be of mild (35/39 and 16/
17 AEs reported with Regimens A and B, respectively)
or moderate (4/39 and 1/17 AEs reported with Regi-
mens A and B, respectively) intensity, and most were
considered likely related to the investigational medica-
tion (35/39 and 14/17 AEs reported with Regimens A
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Figure 6 Time course of the median total peripheral resistance (TPR) estimated by transthoracic impedance cardiography throughout
the main profiling days. Regimen A: baseline Day 1 (NO treatment), Day 11 (R alone: roflumilast 500 μg once daily) and Day 18 (RF: roflumilast
500 μg once daily and formoterol 24 μg twice daily). Regimen B: baseline Day 1 (NO treatment), Day 8 (F alone: formoterol 24 μg twice daily)
and Day 18 (FR: formoterol 24 μg twice daily and roflumilast 500 μg once daily).
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Page 10 of 14and B, respectively). There were no severe or serious
AEs and no AEs led to premature discontinuation from
the trial.
Discussion
Roflumilast improves lung function in patients with
COPD who are also treated with a long-acting broncho-
dilator [13]; accordingly, the concomitant administration
of roflumilast and a b2-adrenoceptor agonist in patients
with COPD is of interest. The present study investigated
whether relevant drug-drug interactions might occur
with the combination of oral roflumilast and inhaled
formoterol. The steady-state plasma pharmacokinetics of
roflumilast and its active metabolite roflumilast N-oxide
were not altered by the addition of formoterol; similarly,
the steady-state pharmacokinetics of formoterol were
unaffected by the addition of roflumilast. Concomitant
administration of inhaled formoterol resulted in changes
that were less than 1% in peak concentration and expo-
sure compared with roflumilast alone treatment There-
fore, this co-administration is unlikely to result in
clinically relevant interactions.
Cardiovascular effects were investigated by ZCG,
which enabled measurement of STIs and allowed deriva-
tion of method-specific non-invasive estimates of systo-
lic pump function [35,43]. These ZCG/STI methods are
particularly sensitive to within-subject positive inotropic
and vasodilatory cardiovascular changes, especially when
chronotropic and inotropic reflexes are triggered by
vasodilatation (’chrono-inodilatory’ responses) [34,44].
Such measures are affected by changes in posture and
food intake [45-47]. In all these measures the detectable
effects were small. With formoterol alone there was a
discrete trend towards a slightly higher HR, shorter PEP,
Table 5 Pharmacodynamic measures - Regimen B: treatment medians and treatment contrasts
Untransformed pre-dose morning values
Median Point estimate (95% CI)
Variable Day 1 Day 8 (F) Day 18 (F+R) Day 8-Day 1 Day 18-Day 8 Day 18-Day 1
HR (bpm) 58 66 62 5 (2 to 9) -1 (-4 to 3) 4 (2 to 7)
PEP (ms) 105 97 98 -7 (-22 to 7) 3 (-9 to 17) -5 (-19 to 20)
QS2 (ms) 434 431 445 -4 (-18 to 9) 4 (-7 to 13) 2 (-13 to 16)
dZ/dt (Ω/s) 1.81 1.94 1.82 0.06 (-0.07 to 0.19) -0.08 (-0.37 to 0.07) -0.03 (-0.30 to 0.16)
CO (L/min) 9.7 9.7 10.3 0.7 (-0.9 to 2.0) -0.5 (-1.7 to 0.6) 0.3 (-1.7 to 2.1)
TPR (dyn.s.cm
-5) 657 668 709 -18 (-198 to 70) 28 (-80 to 100) -36 (-186 to 105)
Untransformed post-dose maximum and minimum values
dmax (U) dmin (U)
Median Point estimate (95% CI) Median Point estimate (95% CI)
Variable Day 1 Day 8 (F) Day 18 (F+R) Day 8-Day 1 Day 1 Day 8 (F) Day 18 (F+R) Day 8-Day 1
HR (bpm) 62 72 72 9 (5 to 11) 51 62 60 7 (3 to 10)
PEP (ms) 122 117 116 -4 (-14 to 2) 87 84 85 0 (-7 to 6)
QS2 (ms) 459 440 445 -14 (-27 to 4) 424 408 410 -13 (-22 to -3)
dZ/dt (Ω/s) 2.05 2.10 2.20 0.01 (-0.15 to 0.21) 1.53 1.64 1.60 0.03 (-0.13 to 0.17)
CO (L/min) 9.8 11.8 11.8 1.7 (0.6 to 2.6) 8.4 8.2 8.0 0.5 (-0.5 to 1.4)
TPR (dyn.s.cm
-5) 870 882 865 -49 (-160 to 80) 655 561 556 -96 (-188 to -24)
Day 1-matched post-dose maximum and minimum values
dmax (δ)d min (δ)
Median Point estimate (95% CI) Median Point estimate (95% CI)
Variable Day 8 (F) Day 18 (F+R) Day 18-Day 8 Day 8 (F) Day 18 (F+R) Day 18-Day 8
HR (bpm) 16 14 -2 (-6 to 2) -2 -3 -1 (-2 to 1)
PEP (ms) 25 21 3 (-19 to 4) -26 -25 0 (-4 to 4)
QS2 (ms) 13 15 4 (-7 to 13) -47 -37 8 (-1 to 15)
dZ/dt (Ω/s) 0.32 0.28 0.05 (-0.16 to 0.17) -0.29 -0.37 -0.05 (-0.27 to 0.15)
CO (L/min) 2.9 3.3 0.0 (-1.0 to 1.5) -0.6 -0.6 -0.4 (-1.3 to 0.6)
TPR (dyn.s.cm
-5) 61 66 -18 (-95 to 73) -221 -224 -42 (-107 to 35)
CO, cardiac output; dmax, post-dose maximum values; dmin, post-dose minimum values; dZ/dt, rate of change of the transthoracic impedance; HR, heart rate; PEP,
pre-ejection period; QS2, total electromechanic systole; TPR, total peripheral resistance.
Medians for baseline (Day 1), formoterol alone (F; Day 8) and formoterol plus roflumilast (F+R; Day 18) with the corresponding point and 95% confidence interval
(CI) estimates for untransformed (U) morning pre-dose values, untransformed post-dose maximum and minimum values (dmax and dmin), and Day 1-matched (δ)
post-dose maximum and minimum values.
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Page 11 of 14increased CO and decreased TPR; these changes are
likely to reflect a vasodilatory effect of formoterol
[48,49]. Roflumilast had no effect on the ZCG/STI cri-
teria and did not appear to potentiate the effects of
formoterol.
Electrocardiographic investigations confirmed a slight
increase in HR for formoterol, which was associated
with an HR-dependent shortening of the QT interval
with no change in HR-corrected QTc. Accordingly,
there was no indication of a safety-relevant cardiovascu-
lar drug-drug interaction.
There was a slight decrease in fasting serum glucose
level with roflumilast, which did not induce any hypo-
glycaemia. This effect was blunted when formoterol was
administered concomitantly. Formoterol is known to
increase serum glucose concentrations at supra-thera-
peutic levels [50]; however, at the 24 μgd o s eu s e di n
this study, there was only a slight increase in serum glu-
cose level when formoterol was administered both alone
and in combination with roflumilast. Supra-therapeutic
doses of b2-agonists are also associated with decreased
serum potassium concentrations [50,51]; in this study, a
mild but consistent decrease was seen with formoterol,
which was unaffected by concomitant roflumilast. A
mild decrease in serum potassium level was also seen
with roflumilast.
None of the other parameters examined (blood pres-
sure, body temperature, clinical laboratory tests) showed
safety-relevant changes that might be attributable to
roflumilast, formoterol or their combination. The
reported AEs were generally mild, with no severe or ser-
ious AEs, and mostly reflected the known properties of
the investigated medications. There were some differ-
ences between the two regimens with regard to the inci-
dence of tremor: tremor was reported 13 times when
formoterol was added to roflumilast (11 times in Regi-
men A and twice in Regimen B), but was not observed
when roflumilast or formoterol were administered alone
(Regimens A and B respectively).
Although this study was performed in healthy men,
results from clinical trials conducted in the roflumilast
target population - patients with severe COPD, chronic
bronchitis and a history of exacerbations - also support
the absence of any relevant interaction between roflumi-
last and long-acting b2-adrenoreceptor agonists. The
two 1-year roflumilast pivotal studies (M2-124 and M2-
125) were conducted in 3091 patients, approximately
half of whom were receiving concomitant b2-adrenore-
ceptor agonists [8]. In a pooled analysis of the two stu-
dies, roflumilast proved effective irrespective of b2-
adrenoreceptor agonist use, and the overall pattern of
AEs with or without concomitant b2-adrenoreceptor
agonists was similar to that reported across all patients;
there was no indication that roflumilast increased AEs
associated with b2-adrenoreceptor agonists (such as
tachycardia or cardiovascular events), and the co-
administration of the two drugs did not increase the
frequency of events associated with roflumilast alone
[52]. Similar results were observed in a 6-month study
(M2-127) conducted in patients with moderate to
severe COPD receiving concomitant salmeterol [13].
Furthermore, a population pharmacokinetic analysis of
roflumilast and roflumilast N-oxide [53] indicated that
only a slight increase (12.6%) in tPDE4i is expected in
patients with COPD compared with healthy indivi-
duals. The fact that during the clinical development of
roflumilast the co-administration with long-acting b2-
adrenoreceptor agonists was evaluated in patients with
COPD for periods of up to 1 year also suggests that
safety issues can be excluded, not only in the short
term considered in this crossover study, but also in
chronic use.
Given that b2-adrenoreceptor agonists can be used in
combination with inhaled corticosteroids in the sympto-
matic treatment of severe COPD, concerns may arise
regarding the addition of roflumilast to this therapeutic
combination. Results from two 1-year randomised clini-
cal trials (M2-111 and M2-112) in patients with severe
and very severe COPD showed that the co-administra-
tion of inhaled corticosteroids does not affect the AE
profile of roflumilast [55]. Furthermore, a drug-drug
interaction study evaluating the effects of the co-admin-
istration of roflumilast and budesonide, a commonly
used inhaled corticosteroid metabolised by CYP3A
enzymes [54], revealed no relevant pharmacokinetic
interactions and no alteration of the safety and tolerabil-
ity profiles of either drug in healthy volunteers [24]. As
mentioned earlier, roflumilast is metabolised by parallel
CYP pathways, which suggests that specific CYP indu-
cers or inhibitors are unlikely to alter its pharmacoki-
netic profile significantly. Although the combination of
roflumilast, formoterol and inhaled corticosteroids has
not been specifically investigated, based on these obser-
vations it is unlikely that the concomitant administra-
tion of the three drugs will cause relevant drug-drug
interactions.
Conclusions
In summary, the study results demonstrate that conco-
mitant administration of oral roflumilast and inhaled
formoterol under steady-state conditions does not affect
the pharmacodynamics or pharmacokinetics of either
drug. In particular, there was no evidence of a relevant
pharmacodynamic interaction with regard to myocardial
repolarisation or cardiac function in general. Moreover,
the concomitant administration of roflumilast and for-
moterol did not negatively influence the safety profile of
either drug.
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